about
Systemic lupus erythematosus: strategies to improve pregnancy outcomesAntithrombotic Treatment for Recurrent Miscarriage: Bayesian Network Meta-Analysis and Systematic ReviewAnti-inflammatory and immunosuppressive drugs and reproductionAntiphospholipid syndrome: a series of surgical emergencies and the current evidence for its management.Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients.Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin.Hughes syndrome (the antiphospholipid syndrome): a disease of our time.Current treatment of antiphospholipid syndrome: lights and shadows.Caesarean section in a case of systemic lupus erythematosus.Update on systemic lupus erythematosus pregnancyTheodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammationLow molecular weight heparin in pregnancy: current issues.A Case of Microangiopathic Antiphospholipid-Associated Syndromes during Pregnancy: Review of the LiteratureNon-coeliac gluten sensitivity and reproductive disorders.Laboratory diagnosis and management challenges in the antiphospholipid syndrome.Antiphospholipid antibodies and pregnancy loss: a disorder of inflammationExcessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.The management of rheumatic diseases in pregnancyHughes syndrome (the antiphospholipid syndrome): 25 years old.New developments in lupus-associated antiphospholipid syndrome.Complement inhibition keeps mothers calm and avoids fetal rejection.Updates on lupus and pregnancy.Complement activation and pregnancy failure.Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression.Management of subsequent pregnancy after antepartum stillbirth. A review.'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.Complement in pregnancy: a delicate balance.Nanotoxicity: a growing need for study in the endocrine system.Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?Reproduction and autoimmune disease: important translational implications from embryo-maternal interaction.Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome.Obstetric antiphospholipid syndrome and long term arterial thrombosis risk.Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family.Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only.Investigation of recurrent miscarriages.Reproductive immunology: current status and future directions (part I).Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.Risk of stratified therapies for antiphospholipid antibody syndrome (APS) in pregnancy: is tailored treatment ready for prime time?Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials.The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience.
P2860
Q26741149-7F5CB498-596B-420F-BAD4-A3EFA02549A1Q26777548-046FC5BD-C5A0-4989-8294-78EA83817F9BQ28218219-93A46EE5-4C40-48E6-8142-84658BE06A8AQ33371908-A87340CC-E73E-4D92-A28F-DAB6790E6AACQ33375598-3AA5FAD6-5EDF-4EFD-8B07-FBFA782E0DB4Q33378067-592F7958-8935-436A-9169-7AE47F77BAF8Q33393146-849C38E7-9323-40F2-91A1-B994C175BF0CQ33423959-24EC8414-980E-4B46-B79C-D9678593F2A0Q33731619-E7A863FD-8000-4728-8EE4-BD90F56693EFQ35756117-A40E70AF-FFB7-4284-823D-466E7AAFC28FQ35778578-3EB9363E-E5F2-47D0-A094-8A0BD25CFEFDQ36051434-0FAD02DB-7F3F-470C-952B-399A584596B4Q36090804-FEDDBF52-16A8-4845-8B19-F06CB4163983Q36145105-93837538-D3EB-4501-B4ED-92B346131F6AQ36458164-CCD9BB5D-2194-4837-8402-CCD4B4608284Q36468176-D364D87F-3D74-4E7B-A74E-3FF0D6ACAA47Q36470411-F8E11375-70D3-45D1-A807-52800D79C8DAQ37047839-050B7CAF-4DFE-4F24-84E9-BEC91FB32761Q37101366-227180D0-0C89-47F5-8A35-2FC1A5E94559Q37168035-366F77F3-837C-4480-B833-DC5BFF8D23B6Q37248466-13633B7B-39B3-4CAB-8238-8CBC4A74990BQ37522808-5EAE94C0-83C4-4C0B-9ECF-1DA536C85DD6Q37638376-174A7385-D6D1-4619-A586-673F67465CA7Q37645693-4B408A93-6A41-454A-AFFD-9B276096C3A2Q37760935-E9F94355-8354-43CE-8798-83B4527D7E5BQ37838098-65ECBB44-1499-4A4A-BFD9-8E4B3F9F537CQ38038295-59C71156-E772-43BD-8C9B-F58F5B2A2A63Q38080803-4D9B2376-D75C-4D63-8D1F-D44338F50175Q38089684-BA77A785-1883-44B2-B205-3F8A18B3E681Q38119553-227E1AC1-5EA2-4973-84ED-CA23B1D0DA00Q38591312-7918B733-6DA0-4E3D-B93A-370DACF4EF10Q38658401-B8683838-45E3-42B3-B559-F1224C53E841Q40249655-BBD1905E-A7FD-4008-948A-D336673C5FF4Q40396553-EE33D104-FE90-4FB3-90F9-450A103D8FD3Q42589171-D32616D3-D30F-42C2-B356-0A4D4A444E3AQ43242936-24B0DB18-A5EE-43BB-8AC9-1F2EB09D6577Q45111033-A6C94E13-50F9-4292-A035-1DED423CEC23Q45880838-78BE9C48-CC90-4BF4-9AC1-67F73FAD26ABQ47407572-90F8060B-2993-480D-9AB2-0A97B493D7B6Q47416196-CA804601-4D96-4A76-85F2-3BD3E21B9B74
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Management of the obstetric antiphospholipid syndrome.
@ast
Management of the obstetric antiphospholipid syndrome.
@en
type
label
Management of the obstetric antiphospholipid syndrome.
@ast
Management of the obstetric antiphospholipid syndrome.
@en
prefLabel
Management of the obstetric antiphospholipid syndrome.
@ast
Management of the obstetric antiphospholipid syndrome.
@en
P2860
P356
P1476
Management of the obstetric antiphospholipid syndrome.
@en
P2093
D Ware Branch
P2860
P304
P356
10.1002/ART.20105
P577
2004-04-01T00:00:00Z